AffiliationOxford Outcomes, an ICON plc Company, Seacourt Tower, West Way, Oxford, OX2 0JJ, UK
MetadataShow full item record
AbstractNeuroendocrine tumours (NETs) are a rare form of neoplasm that can arise in most organs of the body and which share many common pathologic features. Although curative surgery can be conducted for patients with localised disease, once progression occurs and the disease becomes metastatic or un-resectable, treatment aims to extend life and maintain quality-of-life for as long as possible. The aim of the study was to elicit utilities for health state vignettes describing the burdens associated with receiving therapy for advanced NETs.
CitationElicitation of health state utilities in neuroendocrine tumours. 2012, 15 (4):681-7 J Med Econ
JournalJournal of Medical Economics
- Elicitation of health state utilities in metastatic renal cell carcinoma.
- Authors: Swinburn P, Lloyd A, Nathan P, Choueiri TK, Cella D, Neary MP
- Issue date: 2010 May
- Elicitation of health state utilities in soft tissue sarcoma.
- Authors: Shingler SL, Swinburn P, Lloyd A, Diaz J, Isbell R, Manson S, Benson C
- Issue date: 2013 Sep
- Patient-reported health state utilities in metastatic gastroenteropancreatic neuroendocrine tumours - an analysis based on the CLARINET study.
- Authors: Meng Y, McCarthy G, Berthon A, Dinet J
- Issue date: 2017 Jun 29
- Health state utilities for metastatic breast cancer.
- Authors: Lloyd A, Nafees B, Narewska J, Dewilde S, Watkins J
- Issue date: 2006 Sep 18
- Utilities for treatment-related adverse events in type 2 diabetes.
- Authors: Shingler S, Fordham B, Evans M, Schroeder M, Thompson G, Dewilde S, Lloyd AJ
- Issue date: 2015 Jan